**Null Results in Brief**

**No Association between GPX1 Pro\(^{198}\)Leu and Breast Cancer Risk**

David G. Cox,\(^1,2\) Susan E. Hankinson,\(^1,3\) Peter Kraft,\(^1,2\) and David J. Hunter\(^1,2,3\)

\(^1\)Department of Epidemiology and \(^3\)Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, and \(^3\)Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

**Introduction**

Polymorphisms in the antioxidant selenoprotein glutathione peroxidase (GPX1) have been proposed to be associated with lung cancer (1) and breast cancer (2). In particular, the Leu allele of the Pro\(^{198}\)Leu polymorphism has been shown to have lower activity in MCF-7 cell lysates stimulated with sodium selenite (2). This polymorphism was strongly associated with risk of lung cancer (1); a significant association [odds ratio (OR), 1.9; 95% confidence interval (95% CI), 1.02-3.58] in a study of cancer (1); a significant association [OR, 1.9; 95% CI, 1.02-3.58] in another study (3). We assessed the association between GPX1 polymorphisms and breast cancer risk in the prospective Nurses’ Health Study.

**Materials and Methods**

Detailed information regarding the design of this nested case-control study (cases, \(n = 1,323\); controls, \(n = 1,910\)) has been published previously (3). In brief, 32,826 women who were free of diagnosed breast cancer were followed for incident disease from time of blood sample collection in 1989 and 1990 up to May 31, 2000. The two single nucleotide polymorphisms studied [rs3448 and Pro\(^{198}\)Leu (rs1050450)] were chosen as haplotype-tagging single nucleotide polymorphisms from the four single nucleotide polymorphisms in the National Cancer Institute’s SNP500 database (http://snp500cancer.nci.nih.gov/home.cfm). Briefly, haplotype genotyping analysis was done by the Taqman Allelic Discrimination method (Applied Biosystems, Foster City, CA) using primers and probe sequences available from the SNP500 database. Genotype-specific ORs and 95% CIs were calculated using unconditional logistic regression and were adjusted for age, age at menopause, postmenopausal hormone use, body mass index at age 18 years, weight gain since age 18 years, benign breast disease, and family history of breast cancer. ORs in relation to tumor stage and size were calculated in cases only, with <4 nodes involved and tumor size ≤2 cm being the reference categories. In these analyses, we compared carriers of the rare allele with noncarriers. Haplotype frequencies in pooled cases and controls were estimated using PROC HAPLOTYPE and linkage disequilibrium was calculated using PROC ALLELE in the SAS System version 8.0 (SAS Institute, Cary, NC). Regression substitution (5) and unconditional logistic regression (adjusted as above) were used for haplotype association testing, with the G-Pro haplotype as the reference category. Power was calculated using STPLAN (http://calculators.stat.ucla.edu/powercalc/).

**Results**

Both polymorphisms were in Hardy-Weinberg equilibrium, and significant linkage disequilibrium existed between them (\(r = 0.4, D' = 1.00\); \(P < 0.001\)). There was no difference in genotype frequency between our control group and that of Hu et al. \((P = 0.26, \text{Fisher's exact test})\). No association was observed between either GPX1 genotype or the associated haplotypes and breast cancer risk (Table 1). No association was seen between GPX1 alleles and advanced disease [≥4 involved nodes \((n = 81)\) compared with <4 nodes \((n = 967)\) involved: OR, 1.09; 95% CI, 0.83-1.44]. Additionally, rare GPX1 alleles were not significantly overrepresented among larger tumors [≥2 cm \((n = 245)\) compared with ≤2 cm \((n = 964)\): OR, 1.09; 95% CI, 0.83-1.44]. Lastly, no association was seen with any haplotype and tumor size or progression.

**Conclusions**

We did not observe an association between either the Pro\(^{198}\) or the Leu\(^{198}\) allele in the GPX1 gene and breast cancer risk among Caucasian women. We had >99% power to detect a significant relative risk of 1.9 (as reported by Hu et al.) for homozygous carriers of the Leu allele compared with women homozygous for the Pro allele. It is possible that the association between this allele and breast cancer risk shown by Hu et al. could actually be explained by loss of heterozygosity due to the use of tumor DNA as opposed to peripheral blood from patients in their study. However, no association between
the Leu198 allele and tumor progression or size was seen in the present study. Our study is >5 times larger than the study of Hu et al., suggesting that our result is less likely to be influenced by chance fluctuations in the case or control genotype frequency.

References


Table 1. The relationship between GPX1 genotype and breast cancer risk

<table>
<thead>
<tr>
<th>GPX1 genotype, n (%)</th>
<th>Pro198Pro</th>
<th>Pro198Leu</th>
<th>Leu198Leu</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>581 (47.27)</td>
<td>515 (41.9)</td>
<td>133 (10.82)</td>
</tr>
<tr>
<td>OR (95% CI)*</td>
<td>1.00 (reference)</td>
<td>0.91 (0.77-1.07)</td>
<td>1.07 (0.82-1.40)</td>
</tr>
<tr>
<td>Controls</td>
<td>774 (47.51)</td>
<td>694 (42.60)</td>
<td>161 (9.88)</td>
</tr>
<tr>
<td>OR (95% CI)*</td>
<td>1.00 (reference)</td>
<td>1.01 (0.85-1.19)</td>
<td>1.15 (0.84-1.59)</td>
</tr>
</tbody>
</table>

Table 1. The relationship between GPX1 genotype and breast cancer risk

<table>
<thead>
<tr>
<th>GPX1 haplotype, n (%)</th>
<th>G-Pro</th>
<th>A-Pro</th>
<th>G-Leu</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases (n = 1,293)</td>
<td>0.42</td>
<td>0.26</td>
<td>0.32</td>
</tr>
<tr>
<td>Controls (n = 1,695)</td>
<td>0.43</td>
<td>0.26</td>
<td>0.31</td>
</tr>
<tr>
<td>OR (95% CI)*</td>
<td>1.00 (reference)</td>
<td>1.09 (0.83-1.44)</td>
<td>1.00 (0.77-1.30)</td>
</tr>
</tbody>
</table>

*Estimated by unconditional logistic regression and adjusted for age, age at menopause, postmenopausal hormone use, age at menarche, weight gain since age 18 years, history of benign breast disease, and family history of breast cancer.
† Haplotype frequencies in case and control groups as estimated via PROC HAPLOTYPE, with all haplotypes and risk factors. In the model, the haplotype A-Leu was not observed in either group.
No Association between \textit{GPX1} Pro\textsuperscript{198}Leu and Breast Cancer Risk

David G. Cox, Susan E. Hankinson, Peter Kraft, et al.